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Abstract
The surface HIV-1 exterior envelope glycoprotein, gp120, binds to CD4 on the target cell surface to induce the co-
receptor binding site on gp120 as the initial step in the entry process. The binding site is comprised of a highly conserved
region on the gp120 core, as well as elements of the third variable region (V3). Antibodies against the co-receptor
binding site are abundantly elicited during natural infection of humans, but the mechanism of elicitation has remained
undefined. In this study, we investigate the requirements for elicitation of co-receptor binding site antibodies by
inoculating rabbits, monkeys and human-CD4 transgenic (huCD4) rabbits with envelope glycoprotein (Env) trimers
possessing high affinity for primate CD4. A cross-species comparison of the antibody responses showed that similar HIV-1
neutralization breadth was elicited by Env trimers in monkeys relative to wild-type (WT) rabbits. In contrast, antibodies
against the co-receptor site on gp120 were elicited only in monkeys and huCD4 rabbits, but not in the WT rabbits. This
was supported by the detection of high-titer co-receptor antibodies in all sera from a set derived from human volunteers
inoculated with recombinant gp120. These findings strongly suggest that complexes between Env and (high-affinity)
primate CD4 formed in vivo are responsible for the elicitation of the co-receptor-site-directed antibodies. They also imply
that the naı ¨ve B cell receptor repertoire does not recognize the gp120 co-receptor site in the absence of CD4 and
illustrate that conformational stabilization, imparted by primary receptor interaction, can alter the immunogenicity of a
type 1 viral membrane protein.
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Introduction
The human immunodeficiency virus (HIV-1) exterior envelope
glycoprotein, gp120, and the transmembrane glycoprotein, gp41,
are non-covalently associated to comprise the trimeric, functional
viral spike. These glycoproteins mediate entry and represent the
sole virally encoded targets for neutralizing antibodies (nAbs) on
the surface of the virus. The HIV-1 envelope glycoproteins, and
those from related immunodeficiency viruses, are somewhat
unusual in that they mediate target-to-membrane fusion by
receptor-triggered conformational changes rather than by low
pH-mediated fusion events typified by the influenza virus type 1
viral membrane protein, hemagglutinin (HA) [1]. The interaction
of gp120 with the primary receptor, CD4, induces formation or
exposure of a bridging sheet mini-domain that is, along with
elements of the gp120 third variable region (V3), involved with
binding to the co-receptor, CCR5 [2,3,4].
As was previously shown, antibodies against this induced co-
receptor binding site are abundantly generated during natural
HIV infection [5] and may be in part elicited due to the unique
ability of gp120 to undergo receptor-induced conformations
required for the sequential entry process. The co-receptor site
antibodies are termed CD4-induced (CD4i) because following
CD4 binding to gp120 (which functionally induces the co-receptor
binding), these antibodies bind with enhanced affinity to gp120.
The prototype for the co-receptor-directed, CD4i antibodies is
17b. However, it is less well appreciated that several full-length
gp120 proteins actually are recognized by CD4i antibodies like
17b with high affinity (or avidity) even in the absence of the
primary receptor [6]. The co-receptor-directed antibodies do not
generally neutralize most circulating isolates [7]. However, these
antibodies have attracted considerable interest due to the
remarkable post-translational sulfation of a subset of these
antibodies that mimics the functionally important sulfation of the
CCR5 co-receptor N-terminus and their selective VH gene usage
[8,9]. Viral evasion of the CD4i antibodies likely occurs due to the
in vivo selection for viruses that occlude or do not form this highly
conserved region until the virus interacts with the primary
receptor, CD4 [7,10]. Once formed, the conserved site interacts
with the largely invariant HIV co-receptor, CCR5. In contrast to
the ability of affinity-matured CD4i antibodies, which can
recognize the co-receptor site in the absence of CD4 with high
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recognize the same site is not presently understood and may differ
from that of a mature CD4i antibody. Therefore, one aim of this
study was to determine if previously described soluble envelope
glycoprotein trimeric immunogens [11] might elicit CD4i
antibodies in primates that possess a CD4 that is capable of a
high-affinity interaction with the viral spike.
As an immunogen, monomeric gp120 does not elicit broadly
nAbs [12] and has failed as a vaccine in a large clinical trial [13].
Therefore, much of the field has moved toward the design of
soluble trimeric Env immunogens that more closely mimic the
functional spike [11,14,15,16,17,18]. The gp140 trimers which we
have studied are derived from a neutralization resistant primary
isolate, YU2, and are stabilized by heterologous trimerization
domains (foldon) and somewhat improve the elicitation of
neutralizing antibodies when inoculated into small animals
possessing CD4 molecules that do not interact with gp120
[19,20]. However, these stabilized trimeric immunogens have
not been extensively tested in primates, which possess CD4
molecules capable of high affinity interaction with HIV-1 Env.
Here, we demonstrate directly that the elicitation of CD4i
antibodies by Env trimers is dependent upon the in vivo presence
of high-affinity CD4 found in primates, but not present in the wild-
type (WT) rabbits. We definitively demonstrate that the presence
of endogenous primate CD4 is sufficient to generate CD4i
antibodies following inoculation of these same trimers into rabbits
rendered transgenic for human CD4. Consistent with these data,
we also show the presence of co-receptor-directed antibodies in
sera from a subset of patients who participated in the non-
efficacious VaxGen phase III clinical trial using monomeric gp120
as a candidate vaccine. Our findings provide clear evidence that
binding of a type-I viral membrane protein to its primary receptor
can lead to its in vivo altered immunogenicity. It also illustrates
that, in contrast to antibodies that have the undergone affinity
maturation, the naı ¨ve B cell receptor repertoire does not recognize
the co-receptor binding site with sufficient affinity to elicit
antibodies against this region in the absence of primate CD4.
Results
Purified soluble Env trimers bind soluble and cell-surface
CD4
Thehighlyglycosylatedgp140-Ftrimersderivedfromtheprimary
isolate YU2; previously referred to as YU2gp140(-)/FT [11] were
purified from the supernatant of transiently transfected mammalian
cells by lentil lectin affinity chromatography followed by chelation
chromatography. In most cases, size exclusion chromatography was
used to isolate the predominant trimeric peak fraction (Fig. S1). To
confirm binding of the trimers to sCD4 independent of avidity
effects, a solution-based binding assay was developed. To begin, 1 to
137 nM of the gp140-F molecules were co-incubated with 2, 4 or
9 nM soluble human 4-domain CD4 (sCD4) in solution. Next, non-
Env-bound sCD4 was captured by RPA-T4 and detected in an
ELISA format to evaluate the relative binding (Fig. 1A). The gp140-
F trimers bind to sCD4 in a concentration dependent manner with
half-maximal binding at approximately 7, 13 and 26 nM respec-
tively. To confirm the specificity of the binding, we introduced a
mutation at position 368 of gp140 such that 368 Asp was changed to
Arg. This mutation (368D/R) was previously shown to specifically
reduce or abrogate CD4 binding of monomeric gp120 [21] and as
expected in this soluble CD4 reporter assay, the gp140 368D/R
trimers did not bind sCD4 at any concentration tested. Since in vivo,
abundant cell-surface CD4 is a potential source for high-affinity
binding of Env, we sought to confirm that the YU2 trimers could
bind to CD4-positive cells derived from non-human primates before
initiating immunogenicity studies. We co-incubated primate periph-
eral blood mononuclear cells (PBMCs) with 2 mg/ml, 10 mg/ml or
20 mg/ml gp140-Ftrimers and stained the cells for CD3, CD4, CD8
and a markerfor dead cells.Trimerbinding tocell-surface-expressed
CD4 was detected with the V3-directed antibody 447-52D on live,
CD3
+/CD4
+/CD8
2 cells by flow cytometry (Fig. 1B; for staining
and gating strategy, see Fig.S2). Similar tothe results obtained inthe
CD4 solution assay, the gp140-F trimers bound to the CD4
+ Tc e l l s
in a concentration- dependent manner. Trimer binding to the CD4
+
cells could be fully abrogated by pre-incubation of 20 mg/ml of the
gp140-F molecules with an excess of sCD4. Further, no binding
could be detected after incubation of the PBMCs with the gp140
368D/R CD4 binding-defective trimers. Together, the data
confirmed that the YU2 gp140-F trimers used in this study bind
both soluble, and importantly, cell-surface CD4 in a dose-dependent
and specific manner.
Co-receptor binding site directed antibody recognition
of the gp140-F trimers
To confirm that the highly purified trimers used in this study
were competent for recognition by 17b, as well as competent for
induction of the CD4i epitope by CD4, we performed both
ELISA-based and surface plasmon resonance (SPR) binding
assays. First, we incubated 3.2 ng/ml to 10 mg/ml of the YU2
gp140-F trimers in solution, without or with an excess of sCD4,
after which gp140-F was captured by 17b on a plate (Fig. 2A).
Consistent with previous data with monomeric YU2 gp120
[6,22,23], the trimers were well recognized by 17b in the absence
of CD4. However, under the conditions of this assay, the relative
binding increases approximately 2 to 5-fold in the presence of
1 ug/ml or 20 ug/ml sCD4, confirming that sCD4 induces better
exposure, by formation or stabilization, of the CD4i site on the
gp120 moieties present in the soluble trimeric context.
We next determined the recognition of the trimers by the
protypic CD4i antibody 17b by Biacore SPR in two formats (Fig 3).
In the first format, the gp140-F trimers were flowed over 17b
immobilized on the surface of chip as the analyte. Because the
Author Summary
A major goal of HIV-1 vaccine research is to design novel
candidates capable of neutralizing the vast array of viruses
circulating in the human population. One approach is to
base the vaccine upon the HIV-1 outer surface envelope
glycoproteins to generate antibodies. However, during
persistent infection in humans, the HIV-1 envelope glyco-
proteins have evolved structural features that limit the
elicitation of broadly neutralizing antibodies. These immune
‘‘decoys’’ divert the antibody response resulting in virus
subpopulations that can escape the host response. A
potential means by which the virus elicits these decoy
responses comes as a by-product of the entry process.
Binding of the HIV-1 envelope glycoproteins to the primary
receptor, human CD4, induces the formation of a second co-
receptor binding site on the envelope glycoproteins, which
then binds to another protein required for viral entry.
Antibodies to the co-receptor binding site are generally
ineffective at neutralizing HIV-1 patient isolates. Here, we
demonstrate the mechanism by which antibodies to the
HIV-1 co-receptor binding site are elicited in animals and
humans injected with HIV-1 envelope glycoproteins and
describe the implications of their formation regarding
natural HIV-1 infection and vaccine design.
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than strict affinity. However, this would be the case if the trimers
were in solution and recognized by the bivalent BCR in multi-
valent array on the surface of a B cell or if the trimers were
displayed on the surface of a CD4
+ lymphocyte. By this means, we
determined that the avidity of the trimers for 17b was nanomolar
to subnanomolar regardless if the trimers were in complex or not
with CD4 (see Fig 3A). To better approximate the actual affinity of
interaction, the 17b antibody was flowed over the gp140-F trimers
immobilized on the chip and the binding was analyzed by bivalent
curve fitting. This analysis also confirmed that recognition of the
trimers by 17b in the absence of CD4 was a high-affinity
interaction in the low nanomolar range (Fig 3B).
Env trimer immunogenicity in monkeys and in rabbits
To assess if in vivo interaction of primate CD4 with HIV-1 Env is
a requirement for elicitation of CD4i antibodies, we utilized the
previously published observations that WT rabbit CD4 is unable
to bind HIV-1 Env [24]. We immunized cynomolgus macaques
and rabbits four times with the YU2 gp140-F trimers formulated
in the GSK Adjuvant System AS01B and confirmed that the
ELISA titers saturated by three inoculations and were roughly
equivalent (data not shown). For neutralization, we first analyzed
the serum samples from individual animals for their ability to
inhibit viral entry against a panel of selected HIV-1 isolates. The
rationale for this analysis was to assess the over-all neutralization
capacity of responses elicited in monkeys versus the rabbits against
HIV-1 to make a comparison of other responses more meaningful
(i.e. CD4i-directed HIV-2 neutralizing antibodies, see below). The
sera were analyzed at a 1 to 5 dilution against a panel of nine HIV-
1 Env pseudotyped viruses in a standardized neutralization assay
using TZM-bl target cells [25,26] (Fig. 4A). Sera derived from
animals of both species potently neutralized the three sensitive
viruses, the lab-adapted HxBc2 (clade B), SF162 (clade B) and
MW.965 (clade C) with values between 90 and 100%. Overall, the
potency and breadth of neutralization for this panel of viruses were
very similar between the monkey and rabbit sera. Subtle cross-
species differences in neutralization were observed, but these were
not statistically significant. For example, sera from the immunized
rabbits tended to display more consistent animal-to-animal
neutralization capacity against the homologous YU2 strain. In
contrast, the sera derived from the monkeys displayed a trend of
greater potency against BaL and the tier 2 isolate SS1196 (clade
B). Sera derived from both species of animals inoculated with the
YU2 trimers sporadically neutralized the DJ293 isolate (clade A),
but poorly neutralized JRFL (clade B), as well as TRO1.1 (clade B;
Figure 2. ELISA analysis of the 17b:trimer interaction. The YU2
gp140-F trimers, at concentrations of 3.2 ng/ml to 10 mg/ml, were
incubated in the presence (closed circles) or absence (filled circles) of
20 mg/ml sCD4, after which recognition of the trimers by the co-
receptor-binding-site-directed antibody, 17b, was analyzed by ELISA.
Because of the oligomeric state of the trimers, this assay likely assesses
binding avidity, however, the precise stoichiometry of CD4 occupancy
of each trimer or the functional ability of each gp120 subunit within the
trimer to bind CD4 is not yet known. The addition of sCD4 to the trimers
resulted in an approximate 5-fold shift in the levels of K maximal
binding, from 9 nM, in the absence of CD4, to 2 nM in the presence of
CD4.
doi:10.1371/journal.ppat.1000171.g002
Figure 1. Soluble Env trimers bind to soluble and cell-surface CD4. (A) sCD4 at concentrations of 2, 4 and 9 nM was co-incubated with YU2
gp140-F trimers (filled circles) or CD4-binding-defective gp140 368D/R trimers (open circles) at concentrations shown. Subsequently, non-trimer-
bound sCD4 was captured in an ELISA format by the anti-CD4 antibody RPA-T4, competing with HIV-1 Env for CD4 binding. RPA-T4-captured sCD4
was detected with the non-competing anti-CD4 antibody, OKT-4 and plotted as shown. (B) Cynomolgus macaque PBMCs were incubated with 2, 10
or 20 mg/ml of YU2 gp140-F trimers, 20 mg/ml gp140-F trimers in the presence of an excess sCD4 (100 mg/ml) or with 20 mg/ml of gp140-F 368D/R
trimers. Cells were stained for CD3, CD4 and CD8 expression and analyzed by flow cytometry. The CD3
+/CD8
2 populations are shown (see
supplemental FigS2 for gating strategy). The y-axis indicates Env binding, as detected with mAb 447-52D, and the x-axis shows CD4 expression. The
CD4
+ cell population was defined as cells detected to the right of the dotted line. The median fluorescence intensity (MFI) of Env binding to the
CD3
+/CD4
+/CD8
2 cell population is shown.
doi:10.1371/journal.ppat.1000171.g001
HIV Co-Receptor Binding Site Immunogenicity
PLoS Pathogens | www.plospathogens.org 3 October 2008 | Volume 4 | Issue 10 | e1000171Figure 3. Biacore analysis of 17b:trimer interactions. The recognition of the gp140-F trimers by 17b IgG was assessed by SPR in two formats as
shown. (A) 17b IgG was immobilized on the sensor surface and the trimers were then flowed over the Biacore chip either with or without pre-
incubation with a 60-fold molar excess of D1D2 CD4. An approximation of the ‘‘functional affinity’’ of each interaction is presented as calculated by
1:1 Langmuir binding curve fitting. These values likely represent avidity due to the oligomeric state of the gp140-F trimers as the analyte. In this
format, the off-rate value was difficult to accurately assess due to the very slow rate of dissociation and may overestimate the functional affinity or
avidity. Nevertheless, this is clearly an avid reaction and the on-rates shown here agree with previous reports of the affinity values of monomeric
gp120 recognition by monomeric 17b Fab, which is likely the best estimate of affinity [6]. (B) In the other orientation, the trimers were immobilized
on the chip surface and 17b was used as the analyte. The affinity was calculated using bivalent curve fitting since the 17b IgG is dimeric. The value
derived by this analysis indicates a high-affinity, low nanomolar interaction of the 17b IgG with the trimers in the absence of CD4, as shown.
doi:10.1371/journal.ppat.1000171.g003
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the neutralization activity elicited by the current immunogen design.
Perhaps the subtle differences observed in the neutralization potency
against some of the isolates between sera derived from the monkeys
versus the rabbits is due to slight differentials in the elicited antibody
repertoires, however, in general, the data highlights the overall
similarities in the elicited neutralization capacity.
To detect if there is a species-difference in specific antibody
elicitation against the co-receptor site of gp140-F trimers, we
analyzed the sera in the same assay format as above but against
virus pseudotyped with Env from an HIV-2 isolate, 7312
(containing a V434M amino acid change). While this virus is
relatively insensitive to antibodies raised against HIV-1 Env it
becomes highly sensitive to anti-HIV-1 CD4i-antibodies in the
presence of sub-inhibitory concentrations of sCD4, facilitating the
specific detection of such antibodies [5]. Consistent with data from
HIV-1 infected individuals [5,27] and gp140-inoculated humans
(GMS, unpublished observations), CD4i-antibodies detected by
this assay were abundant in sera from all five monkeys (ID50 titers:
55, 91, 268, 479 and 2618; Fig 4B). We could detect low-level
cross-neutralization of HIV-27312/V434M in sera from four of the
five monkeys, consistent with what had been observed previously
from some HIV-1 infected humans [5]. Following these results, we
analyzed three cynomolgus macaques that had been inoculated
with the YU2 gp140-F trimers in Ribi adjuvant 2 times and at a
similar dose, and detected CD4i antibodies in these animals with
ID 50 values of 21, 27 and 198 (Fig S3). The lower levels of CD4i
antibodies relative to those elicited by trimers formulated in
AS01B, correlated with similarly lower potency of neutralization
against the HIV-1 isolate, MN (Fig S3). We also detected CD4i
antibodies in 5 out of 5 cynomolgus monkeys primed with Semliki
Forest virus (SFV) particles expressing the YU2 gp140-F trimers
and boosted with trimeric protein with ID50 values of 57, 1619, 44
and 335 and in 3 out of 3 baboons immunized with YU2 gp140
molecules rendered trimeric with a modified GCN4 motif [16] in
Ribi adjuvant (data not shown). Taken together, these data clearly
demonstrate that elicitation of CD4i antibodies by Env trimers in
non-human primates is a highly reproducible and commonly
elicited response and can occur at low levels when Env is expressed
from a viral vector (SFV; not shown).
Figure 4. HIV-1 and HIV-2 neutralization. (A) Overall neutralization activity against nine different HIV-1 Env pseudotyped viruses in serum
samples from monkeys and rabbits following 4 immunizations with the YU2 gp140-F trimers. Sera were screened at a 1:5 dilution (except against
MW.965, which was done at a 1:10 dilution of the sera) for neutralization activity. Neutralization between 70 and 79% is indicated in yellow, while
neutralization between 80 and 100% is indicated in red. Pre-bleed serum sample effects on viral entry were negligible; BSA adjuvant control animals
and MuLV pseudotyped virus were also included as negative controls. (B) Detection of CD4i antibodies in serum samples from immunized
cynomolgus macaques and rabbits after 4 immunizations. Serum samples from monkeys and rabbits were titrated for neutralization activity against
HIV-27312/V434M. Data are presented as the reciprocal dilution of immune serum resulting in a 50% inhibition of entry (ID50) in the absence (white bars)
or presence (blue bars) of 9 nM sCD4. (C) A 17b blocking assay was performed using sera elicited from monkeys (blue) and WT rabbits (black). For the
assay, the sera were serially diluted in a 96 well format in which the wells were pre-coated with HXBc2 core gp120 glycoproteins. Following washing,
biotinylated 17b was added to each well and the ability of the sera to block 17b binding was assessed by ELISA.
doi:10.1371/journal.ppat.1000171.g004
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serum from any of the WT rabbits (Fig 4B), suggesting that the
elicitation of CD4i-antibodies is dependent on the in-vivo presence
of CD4 with affinity for the YU2 trimers in the non-human
primates. Alternatively, it might be that rabbits lack B cell
receptors (BCR) in their naı ¨ve repertoire with the ability to
recognize the HIV-1 co-receptor binding site while the monkeys
possess such a capacity.
While the HIV-2 assay detects antibodies specific for the co-
receptor binding site, we wanted to confirm these results by
performing an ELISA based assay where serum from immunized
animals were tested for their ability to compete with a biotinylated
17b antibody for binding to gp120. It is known that antibodies not
directly directed against the co-receptor site are capable of
competing with 17b for binding to gp120 [28]. To minimize such
indirect effects, we analyzed the ability of sera to compete for
biotinylated 17b binding to an HXBc2 gp120 core protein capable
of binding 17b with high affinity (Dey et al, manuscript in
preparation). In this assay format serum samples from monkeys
were able to inhibit 17b binding at an approximately 10-fold
higher dilution than that of serum samples from the rabbits
(Fig 4C). The weak, but detectable, level of antibodies capable of
competing with 17b in serum from rabbit serum may be due to
antibodies recognizing the co-receptor binding elements in the
pre-CD4 induced state or other antibodies that can inhibit 17b
binding, such as CD4 binding site antibodies [28].
Direct interaction of the trimers with primate CD4 might be
expected to expose as well V3, the other element of gp120 involved
in co-receptor interaction [4]. To address this issue, we performed a
binding assay to determine the proportion of V3-specific antibodies
compared toantibodies againstintactgp120 inseraderived from the
3 types of test animals. We observed a slight 1.6-fold average higher
proportion of antibodies against V3 in serum samples from primates
than in WT rabbits that was not statistically significant (Fig S3). The
huCD4 rabbits, although possessing lower gp120 and V3 binding
titers compared to WT animals, also displayed a slightly greater
proportion of V3-specific antibodies. The lack of a significant
increase in V3-directed antibodies may be due to maximal exposure
of V3 on gp140 as we could see no enhancement of binding of a V3-
specific antibody to the trimers following addition of CD4 (not
shown) consistent with a previous study [28].
Immunization of human-CD4-transgenic rabbits with
trimers
To address if the presence of primate CD4 was required for the
elicitation of CD4i antibodies from the gp140-F trimeric immuno-
gens, we used rabbits previously engineered to be transgenic for
human CD4 (huCD4) [24]. These rabbits were generated from the
NewZealandWhite(NZW)background,andarerelativelysimilarin
their genetic background to the out-bred NZW WT rabbits used for
the initial immunogenicty analysis above. The huCD4 transgenic
rabbits allowed us to perform controlled immunogenicity experi-
ments to determine if the in vivo presence of primate CD4 allows for
BCR recognition of the YU2 gp140-F co-receptor site and
subsequent elicitation of CD4-induced antibodies in rabbits. Before
initiating the immunogenicity experiment, we confirmed that the
huCD4 transgenic animals, ranging from 2 to 5 years of age, still
expressed human CD4 on their PBMCs as follows. Incubation of
20 mg/ml gp140-F trimers with PBMCs from WT and huCD4
rabbits and analysis by flow cytometry using species-specific cellular
makers (for staining and gating strategy, see Fig. S5) confirmed that
only PBMCs from the transgenic animals can bind the gp140-F, and
that binding occurred only on cells co-expressing human and rabbit
CD4 (rCD4; Fig. 5A). These results are consistent with the initial
design of the transgenic rabbits to restrict expression of huCD4 only
to cells also co-expressing rCD4 by use of a cell-type-specific
promoter [24].
Five huCD4 rabbits were inoculated with the YU2 gp140-F
trimers formulated in AS01B adjuvant by an identical regimen as
the WT rabbits and monitored for the appearance of CD4-
Figure 5. Characterization of huCD4 rabbit PBMCs and HIV-2 neutralization. (A) CD4 expression and YU2 gp140-F trimer binding to PBMCs
from WT and huCD4 rabbits (T4-19, T4-24, T4-41, T4-44 and T4-45) was analyzed by flow cytometry. PBMCs were incubated with 20 mg/ml of the
gp140-F trimers and stained with an anti-rabbit CD4 antibody (x-axis) followed by detection of trimer binding with the mAb 447-52D (y-axis) (see
supplemental Fig S5 for gating strategy). rCD4
+/Env
2 cells are located in the lower right quadrant while rCD4
+/Env
+ cells are located in the upper
right quadrant. The percentage of cells detected in each quadrant is indicated. (B) ID50 HIV-27312/V434M neutralization in the presence of 9 nM sCD4
by serum samples from WT and huCD4 rabbits (blue) after 3 immunizations with the gp140-F trimers.
doi:10.1371/journal.ppat.1000171.g005
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antibodies could be detected in the sera from four out of five
huCD4 rabbits after three immunizations with gp140-F trimers
(Fig 5B). The ID50 titers detected were 84, 127, 190 and 4507,
which is comparable with the levels detected in serum samples
derived from immunized monkeys. These data demonstrate that
rabbits have the capacity to induce antibodies against the HIV-1
co-receptor site, but that the in vivo presence of primate CD4 is
required for the elicitation of these antibodies. This most likely
occurs by a direct interaction with primate CD4 and induction of
the co-receptor binding site, consistent with a recent study that
detects CD4i antibodies following inoculation of monkeys with a
CD4-gp120 fusion protein [29]. We also monitored for elicitation
of neutralizing antibodies against HIV-1 pseudotyped virus in
serum samples of these huCD4 rabbits and observed that the titers
were not as consistent and potent for as for the WT rabbits (data
not shown). These results might be due to the relatively advanced
age of the huCD4 rabbits or as a consequence of unanticipated
immune-related effects of the huCD4 transgene. However, as a
slightly diminished immune response in these animals would only
bias the results against the elicitation of CD4i antibodies, this
remains a stringent model to assess the dependence upon primate
CD4 for elicitation of these antibodies.
The 17b antibody can recognize cell-surface, CD4-bound
soluble Env trimers
The elicitation of CD4i antibodies in monkeys and huCD4
rabbits after immunization with YU2 trimers suggests that the co-
receptor site of gp120 is accessible for BCR recognition: likely on
the surface of CD4
+ PBMCs. Therefore, we investigated if the
prototypic, co-receptor-site-directed mAb, 17b, could bind gp140-
F trimers once they were bound cell-surface CD4. We sought to
confirm that there was adequate accessibility of the CD4-induced
co-receptor binding site on the trimers, once they were removed
from the context of the virus. In the viral spike context, the
induced co-receptor site is apparently not accessible to most CD4-
induced antibodies due to steric constraints. To approximate the in
vivo scenario in which trimers formulated in adjuvant would likely
drain to proximal lymph nodes to encounter abundant CD4
+ cells,
we incubated cynomolgus macaques PBMCs with 20 mg/ml of the
gp140-F trimers and detected CD4-specific binding to live CD3
+/
CD4
+/CD8
2 cells by the V3-directed antibody 447-52D or 17b
using flow cytometry (Fig. 6A). Binding of the gp140-F trimers
could be detected with both antibodies. Recognition of the trimers
by 447-52D verifies that the YU2 gp140-F molecules bind to the
CD4
+ cells, while cell-surface recognition of the trimers by 17b
confirms that the co-receptor site is accessible after trimer binding
to membrane-bound CD4. Similar results were obtained when the
cell-surface binding assay was repeated using human PBMC
targets as shown in Fig 4B. Monomeric gp120 bound to the
human CD4
+ cells was used as a control and displayed the 17b
epitope at levels higher than that of the gp140-F trimers (Fig 6B).
Sera from humans immunized with gp120 possess CD4i
antibodies. Following the observation that the gp120 monomers
bound to cell-surface CD4 displayed the CD4i epitope, we
obtained serum samples from the VaxGen Inc phase III clinical
trial now licensed to the Global Solutions for Infectious Diseases.
Twenty randomly selected sera from trial volunteers that had been
inoculated four times with recombinant gp120 (MN/GNE8
mixture) formulated with alum were assessed for gp120 binding
antibodies by ELISA. All sera exhibited detectable binding titers to
the unmatched YU2 gp120 ranging from 5000 to 100,000
endpoint titers (not shown). We assessed the ability of the sera to
inhibit the entry of MN and, in the presence of CD4, the HIV-2
virus 7312. As shown in Table 1, all sera neutralized not only the
homologous virus, MN, but displayed detectable, relatively high-
titer, cross-neutralizing, co-receptor-directed antibodies against
the CD4-triggered HIV-2 isolate.
Discussion
In this study, we demonstrate that the elicitation of co-receptor
site directed antibodies by the YU2 gp140-F trimers requires the
presence of primate CD4. We show that the relatively homoge-
nous, soluble, stable YU2 trimers bind to human CD4 with high
affinity in a solution-based assay that, by design, should be
independent of oligomeric influences on functional affinity by
avidity-dependent interactions. Analysis of the interaction between
the prototypic co-receptor antibody, 17b, and the trimers
demonstrated that high-affinity and high-avidity binding is
Figure 6. Accessibility of the HIV-1 co-receptor site after CD4
binding. (A). PBMCs from cynomolgus macaques and humans were co-
incubated with20 mg/ml YU2 trimers or(B) with5 mg/ml YU2gp120 (only
human PBMCs). CD4 specific trimer binding (blue) to CD3
+/CD4
+/CD8
2
cells was detected with either the V3-directed mAb, 447-52D (left panels),
or with the co-receptor site-directed mAb, 17b (right panels), by flow
cytometry analysis. Negative control staining (red, both panels) shows the
fluorescence signal obtained in the absence of 447-52D or 17b.
doi:10.1371/journal.ppat.1000171.g006
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primate cell-surface CD4, but not to cell-surface rabbit CD4 was
also shown. WT rabbits and monkeys inoculated with the CD4-
binding YU2 Env trimers formulated in the same adjuvant system
elicited an overall similar pattern of HIV-1 in vitro neutralization
against the viruses tested. However, cross neutralization of HIV-2 in
presence of sCD4, an assay that is diagnostic for the detection of
CD4iantibodies,wasobservedinitiallyinseraderivedfrommonkeys
inoculated with the YU2 trimers but not in WT rabbits. Taken
together, these data strongly suggest that Env-CD4 complexes
generated in vivo upon inoculation are the source for elicitation of the
CD4-induced antibodies following vaccination. This observation
was confirmed by the inoculation of Env trimers into rabbits
transgenic for human CD4 and the detection of CD4i antibodies in
the sera of these animals, in contrast to WT rabbits, revealing
conclusively the mechanismof their generation (see schematic Fig 7).
Consistent with this observation, high levels of co-receptor-directed,
HIV-2 (+CD4) cross neutralizing antibodies were detected in 20 of
20 human serum samples from the VaxGen phase III clinical trial
using monomeric gp120 [13], suggesting that during natural
infection shed, soluble gp120 can elicit these antibodies [30].
The induction of co-receptor site directed antibodies in non-
human primates and humans is consistent with previous reports
that detected the presence of CD4i, co-receptor directed
antibodies in gp140-immunized humans (GMS, unpublished
observations), as well as in naturally infected humans [5,31] and
following SHIV challenge of naı ¨ve non-human primates [29].
However, the mechanistic basis for the elicitation of CD4i
antibodies was not previously addressed in a direct manner. In
this study, we present a controlled experiment, which demon-
strates that the elicitation of the co-receptor binding site antibodies
by Env alone requires the presence of, and likely direct interaction
with, primate CD4. This requirement has not previously been
defined, despite numerous Env trimer immunogenicity experi-
ments performed to date in both monkeys and non-primate species
[17,18,20,32,33]. This is in part, because the HIV-2-based
neutralization assay diagnostic for CD4i antibodies was a relatively
recent development and is more definitive for neutralizing capacity
directed at the co-receptor binding site then are binding assays
employed by us and others previously [23,34,35]. Elicitation of
CD4i antibodies in primates by Env trimers also nicely illustrates
another potential mechanism of immune escape by HIV-1. Not
only does Env binding to CD4 obscure a conserved surface that, if
it was highly immunogenic, might elicit antibodies capable
neutralizing a broad array of isolates (essentially antibodies
mimicking the soluble primary receptor), but the binding event
induces a second conserved and apparently immunogenic region:
the co-receptor binding site. The CD4i antibodies directed against
this region are not generally able to neutralize primary isolates in
vitro [7]. This is likely due to a commonly elicited selection
pressure that renders the co-receptor binding inaccessible to most
antibodies of this type [10]. The inability of the CD4i antibodies to
control HIV-1 infection is supported by data from a recent study
where elicitation of CD4i antibodies can be detected prior to the
detection of autologous virus neutralization capacity in sera
derived from HIV-1 infected patients [27], as well as the data
here, which indicates that they were elicited in the phase III
Vaxgen clinical trial where no protection was observed. However,
a recent study in non-human primates suggests that the presence
of CD4i antibodies (as determined in vitro by the same HIV-2
detection assay as used here) is associated with more rapid viral
clearance following SHIV162P3 challenge [29], illuminating that
this is an area worthy of further investigation.
In the present study, the most likely in vivo source for
presentation of the CD4i region to the humoral immune system
is by direct interaction of the trimers with cell-surface CD4
displayed on CD4-expressing T cells or other CD4-positive cells of
the hematopoetic lineage. It is also possible that low levels of CD4
are shed from CD4
+ cells into interstitial spaces and soluble
complexes are formed. Detection of low levels of sCD4 has been
previously reported in humans [36,37], although in the assay used
here we could not detect soluble CD4 in the sera of animals
examined. It is also possible that trimer binding to cell-surface
CD4 induces shedding of complexes, but we could find no such
evidence for soluble Env-CD4 complexes in the sera.
The implications of inducing the co-receptor binding site has
been discussed extensively at the level of entry, but less so at the
level of antibody elicitation. That the CD4i antibodies are not
elicited by trimers in the absence of CD4, even though the gp140-
F molecules are well recognized by 17b, and that CD4 induction
of the epitope in the trimer context is not a requirement for 17b
binding, may seem to be a bit of a paradox. However, we interpret
these data to indicate that the conformational fixation imparted by
CD4 binding to gp120 is a critical requirement for the naı ¨ve,
germline B cell repertoire to efficiently recognize the site as
opposed to the affinity-matured 17b antibody, which can likely
induce the fit of its epitope in the absence of CD4 (see Schematic
Fig 7). This is more likely to be an affinity limitation of the non-
affinity matured BCR repertoire, although it is possible that it is
somehow related to binding limitations of Ig molecules on the
surface of B cells and epitope accessibility issues.
Another possible interpretation of the data is that elements of
the pre-CD4 co-receptor binding site are immunogenic, but do not
Table 1. Neutralization values present in sera elicited by
gp120 inoculated into humans
Serum sample VIRUS
HIV-2 7312/V4334M+9NM SCD4 HIV-1 MN
ID50 ID80 ID50 ID80
001 4,178 737 24,410 1,925
002 74,789 10,124 141,655 12,343
003 8,890 1,145 11,180 1,051
004 2,452 365 1,181 216
005 15,110 2,279 9,134 1,912
006 1,286 309 1,116 91
007 1,664 406 8,496 577
008 2,002 391 2,340 378
009 2,974 642 46,508 1,485
010 3,226 666 20,787 1,619
011 1,229 226 8,962 369
012 630 94 1,532 14
013 3,601 548 20,572 1,143
014 1,864 339 21,759 1,313
015 292 80 1,351 282
016 5,415 1,162 6,687 967
017 1,904 376 31,204 2,083
018 3,571 661 2,579 383
019 430 115 302 87
020 762 132 6,406 644
doi:10.1371/journal.ppat.1000171.t001
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site induced by CD4. However, the 17b blocking assay, using a
form of the gp120 core with the potential to be recognized by any
antibodies to the co-receptor site indicated that the pre-CD4 state
of the trimers did not elicit many antibodies directed toward this
region compared to those elicited in the presence of primate CD4
(Fig 4C). Also, we cannot rule out that array of gp140 or gp120 on
the surface of CD4+ cells might also enhance the elicitation of
CD4i antibodies in a manner independent of conformational
fixation. However, the study by DeVico et al [29] clearly
demonstrates that covalent gp120-CD4 complexes incapable of
binding cell-surface CD4 efficiently elicit CD4i antibodies, so
Figure 7. Schematic representations of the pre-CD4 and post-CD4 conformations of Env. (A) Based upon the structures of the
unliganded SIV core gp120 [40] and the CD4-bound HIV-1 core [41], the movements of the co-receptor site bridging sheet beta-strands are
highlighted in green. Note that 17b binds to the unliganded HIV-1 core with low affinity (,1 uM) consistent with the ‘‘split orientation’’ of the
bridging sheet revealed by the unliganded SIV core structure. 17b can also recognize full-length gp120 with high affinity [6] and the gp140 trimers as
demonstrated in this study (see Figs 2 and 3). These observations suggest that the bridging sheet may not be in exactly the same conformation in the
full-length protein context as it is in the original gp120 core protein structures with and without CD4. (B) A model of how the co-receptor region
(green) is recognized by the naı ¨ve B cell receptor repertoire. In the left and middle panel, the co-receptor binding site is not formed. Following
binding to high-affinity primate CD4 (likely on the surface of CD4
+ cells), the bridging sheet is formed and locked into a single, CD4-dependent
conformation, which then allows elicitation of co-receptor-site-directed, CD4i antibodies (right panel). The somatically mutated and affinity-matured
17b antibody can recognize either conformation, presumably inducing a proper fit of the unliganded bridging sheet conformation.
doi:10.1371/journal.ppat.1000171.g007
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for their elicitation in the presences of primate CD4.
The implications of the data presented here are also an important
consideration for vaccine candidates designed to elicit neutralizing
antibodies against the conserved gp120 CD4 binding site. The Env
CD4bs likely remains fully accessible in animals without human or
primate CD4, however the elicitation of the CD4i antibodies in
animals with primate CD4 indicates that this is likely not the case in
species harboring CD4 molecules with a high affinity to Env. These
results suggest that a fraction of the population of a CD4-binding-
competent immunogen will interact with primate CD4 and thereby
occlude the CD4 binding region on this protein subset. It is possible
that the subtle differences detected in the neutralization profile
between WT rabbits and monkeys occur as a result of such an
interaction, partially altering the spectrum of antibodies that are
elicited. However, the fractional component of the inoculate which
binds to CD4 as yet remains to be determined, and may not be
absolute as the overall HIV-1 neutralization profile elicited by the
trimers used in this study was similar between the rabbits and the
non-human primates.
It was also previously shown that HIV Env-CD4 interaction
resulted in altered CD4
+ T cell function in vitro [38] and it was
suggested that elimination of Env interaction with CD4 in the
context of vaccination might be beneficial to better elicit functional
T cell help and more potent neutralizing antibody responses. From
that study and the data presented here it will be interesting to
assess if Env variants that do not bind CD4, but still retain the
ability to bind CD4 binding site antibodies might make better
immunogens than do unmodified YU2 gp140-F proteins.
Alternatively, redirecting the immunogen more efficiently to B
cell and antigen presenting cells might also overcome any potential
detrimental effects of Env-based immunogens interacting with
primate CD4. Follow up immunogen trimer design, characteriza-
tion and immunogenicity studies are warranted to clarify these
issues further in the near future.
Materials and Methods
Protein production and purification
Proteins were produced by transient transfection of adherent
293F cells or 293Freestyle suspension cells. The highly glycosy-
lated and His-tag containing YU2gp140-F trimers were captured
and purified from the serum-free media in a three-step process.
First, the protein was captured via glycans over with lentil-lectin
affinity chromatography (GE Healthcare, Uppsala, Sweden). After
extensive washing with PBS the protein was eluted and captured in
the second step via the His-tag by nickel-chelation chromatogra-
phy. (GE Healthcare) then washed and eluted with a 300 mM
Imidazole containing PBS buffer. In some cases the YU2gp140-F
trimers were separated from lower molecular weight forms by the
third step of gel filtration chromatography using a superdex200
26/60 prep grade column by the A ¨KTA Fast protein liquid
chromatography system (GE Healthcare). In contrast, the
YU2gp120 and HXBc2 gp120 core proteins were purified by
capturing the molecules on an IgG17b affinity column. After
extensive washing with PBS, the proteins were eluted from the
column with 100 mM glycine/Tris HCl/150 mM NaCl. pH 2.8
and immediately neutralized with Tris base, pH 8.5.
CD4 solution competition assay
Env protein was co-incubated at concentrations of 0.4 to 46 nM
in PBS with 2, 4 or 9 nM sCD4 at room temperature for 1 h,
allowing for CD4-Env trimer complexes to form. Non-Env bound
sCD4 was captured on a plate pre-adsorbed with 200 ng/well of
the anti-CD4 antibody RPA-T4 (Ebioscience, San Diego, CA).
RPA-T4 binds to domain 1 of CD4 and competes with HIV-1
gp120 for binding. RPA-T4 bound sCD4 was probed with a
biotin-conjugated, non-competitive anti-CD4 antibody, OKT-4
(Ebioscience). Horseradish peroxidase (HRP) conjugated strepta-
vidin (Sigma) followed by the colorimetric peroxide enzyme
immunoassay substrate (3,39,5,59-tetramethylbenzidine; Bio-Rad)
was added to induce a colorimetric change and the reaction was
stopped by adding 1 M H2SO4. OD was read at 450 nm.
Enzyme-linked immunosorbent assay (ELISA)
High-protein-binding MaxiSorp plates (Nunc) plates were coated
with 200 ng/well of mAb 17b in 100 ml of PBS at 4uC overnight
after which the wells were blocked for 2 h at room temperature (RT)
with PBS-2% fat-free milk. The gp140-F trimers, at concentrations
between 3.2 ng/ml to10 mg/ml, werepre-incubated with 20 mg/ml
sCD4for1 hatRT and thenaddedtothewells.Thewellswerethen
probed for 17b bound gp140-F trimer with rabbit anti-gp140-F
polyclonal sera. Addition of HRP conjugated anti-rabbit-Ig (Fc
region) (Jackson Laboratories, Bar Harbor, MN) followed by the
colorimetric peroxide enzyme immunoassay substrate (3,39,5,59-
tetramethylbenzidine; Bio-Rad) was used to induce a colorimetric
change and the reaction was stopped by adding 1 M H2SO4.O D
was read at 450 nm. The 17b binding competition assay was
performed by coating the ELISA plate with 200 ng/well of lectin
from Galanthus nivalis (Sigma), followed by 200 ng/well of HXBc2
core protein. After blocking with 2% fat-free milk, serum was
incubated for 45 minutes at dilutions between 25 and 6400 in a total
volume of 100 ul after which 25 ul of biotin conjugated 17b
antibody was added to a final dilution of 2500 and incubated for an
additional 45 minutes. The plate was probed with HRP conjugated
streptavidin and developed as above.
SPR kinetic analysis
To determine the kinetic constants of YU2gp140-F interaction
with 17b IgG, we performed binding analysis were in two different
formats on a Biacore3000 surface plasmon resonance spectrom-
eter. In one format (Fig 3A and B), YU2gp140-F (without or with
pre-binding to 20-fold molar excess of D1D2 sCD4 for 1 h) was
passed over the 17b IgG surface. Because of the potential
oligomeric interaction of the trimers with 17b IgG presented on
the surface of the chip, this analysis likely measured avidity rather
than simple affinity. However, since the curves approximated
single binding kinetics and we did not know how many monomeric
subunits within the trimers were capable of 17b interaction, curve
fitting was done assuming a 1:1 interaction. In the reverse format
(Fig. 3C), the 17b IgG was passed over YU2gp140-F surface and
functional (or apparent) affinity was calculated using the bivalent
analyte program (Biacore) that derived affinity from the potential
bivalent interaction of the 17b with trimers immobilized on the
chip surface.
To prepare binding surfaces, ligands (7 mg/ml in 10 mM
NaOAc, pH 5.5 buffer) were immobilized on CM5 chip by the
amine coupling method following manufacturer’s protocol. One
flow cell receiving only NaOAc buffer was used as reference
control for correction of background binding. For binding
experiments, analytes were serially diluted at concentrations
ranging from 4.6 nM to 600 nM in the HEPES-EP reaction
buffer. To determine the rate of association, each analyte was
allowed to flow over the activated surfaces at a rate of 30 ml/min
for 3 minutes. Dissociation was determined by washing off bound
analyte for the next 5 min. Likely due to avidity of the oligomeric
analytes, especially in Fig 3A, the rate of dissociation was difficult
to determine and likely represents and over estimate of the actual
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unbound analyte with two injections (60 sec each) of 10 mM
Glycine, pH 3.0. All procedures were performed at RT.
Flow cytometry
Monkey, human and rabbit PBMCs were analyzed by flow
cytometry using a modified LSR I system (BD Biosciences). Data
analysis was performed using FlowJo software (Tree Star, San
Carlos, CA). Staining and gating strategies to detect YU2 trimer
binding to live, CD3
+/CD4
+/CD8
2 cells from primates is
described in Fig. S2. Staining and gating strategy for trimer
binding to rabbit cells is described in Fig. S4. The mAb 447-52D
was a kind gift from Susan Zolla-Pazner (New York University
School of Medicine).
Animals
Five female cynomolgus macaques (Macaca fascicularis)o f
Chinese origin, 5–6 years old, were housed in the Astrid Fagraeus
laboratory at the Swedish Institute for Infectious Disease Control.
Housing and care procedures were in compliance with the
provisions and general guidelines of the Swedish Animal Welfare
Agency. The animals were housed in pairs in 4 m
3 cages, enriched
to give them possibility to express their physiological and
behavioural needs. They were habituated to the housing
conditions for more than 6 weeks before the start of the
experiment, and subjected to positive reinforcement training in
order to reduce the stress associated with experimental procedures.
All immunizations and blood sampling were performed under
sedation with ketamine 10 mg/kg intramuscularly (i.m.). (Keta-
minol 100 mg/ml, Intervet, Sweden) The macaques were weighed
and examined for swelling of lymphnodes and spleen at each
immunization or sampling occasion. Before entering the study, all
monkeys were confirmed negative for simian immunodeficiency
virus (SIV), simian T-cell lymphotropic virus and simian retrovirus
type D. Female New Zealand White Rabbits and male huCD4
New Zealand White transgenic rabbits were housed at BioCon,
Inc (Rockville, MD) or at an animal facility at the National
Institutes of Health according to current regulations. Cynomolgus
macaques were injected once with 200 ug followed by three
injections with 100 mg YU2gp140-F trimer. Rabbits were injected
four times with 50 ug YU2 trimer. All proteins were formulated in
the GSK-AS01B adjuvant system (GlaxoSmithKline, Rixensart,
Belgium) prior to injection unless otherwise stated and all
injections were administered i.m. at an interval of one month.
Sera were collected before the first injection as well as two weeks
after each injection. All procedures were approved by the Local
Ethical Committee on Animal Experiments.
Neutralization Assays
Analysis for HIV-1 and HIV-2 neutralization in serum samples
were performed as previously described [25,26]. Briefly, Env
pseudoviruses were prepared by co-transfecting 293T cells with an
Env expression plasmid containing a full gp160 env gene and an
env-deficient HIV-1 backbone vector (pSG3 Env). For screening, a
single dilution of sera or plasma was used and the percent
neutralization was calculated compared to controls with no sera
added. To determine the dilution of the sera that resulted in a 50%
reduction in RLU against selected viruses, serial dilution assays
were performed and the neutralization dose-response curves were
fit by non-linear regression using a 4-paremeter hill slope equation
programmed into JMP statistical software (JMP 5.1, SAS Institute
Inc., Cary, NC). The results are reported as the serum
neutralization ID50, which is the reciprocal value of the serum
dilution resulting in a 50% reduction in viral entry. Dana Gabuzda
(Dana Farber Cancer Institute) provided the Env plasmid for
YU2. Env plasmids for SF162 and JRFL were provided by
Leonidas Stamatatos (Seattle Biomedical Research Institute) and
James Binley (Torrey Pines Institute), respectively. The Clade A
Env-pseudovirus DJ263.8 was cloned from the original PBMC
derived virus provided by Francine McCutchan and Vicky Polonis
(U.S. Military HIV Research Program). Env plasmids BaL.01 was
recently described by our laboratory [26] and the Env used to
generate the pseudovirus SS1196.1 was previously described [39].
The HIV-2 Env-pseudovirus 7312 containing the V343M
mutation have previously been described [5]. The remaining
functional Env plasmids were obtained from the NIH ARRRP.
Human serum samples
Twenty randomly chosen serum samples were obtained via an
MTA with the Global Solutions for Infectious Diseases. These sera
were derived from volunteers from the VaxGen Inc phase III
clinical trial. At the time of sampling (month 12.5) the participants
had received four injections (month 0, 1, 6 and 12) with the
AIDSVAX B/B vaccine containing 300 ug each of recombinant
HIV-1MN or HIV-1GNE8 derived gp120 in Alum adjuvant [13].
Supporting Information
Figure S1 Biochemical analysis of the YU2 gp140-F trimers.
Found at: doi:10.1371/journal.ppat.1000171.s001 (3.17 MB TIF)
Figure S2 FACS gating strategy for cynomolgus macaque and
human PBMCs.
Found at: doi:10.1371/journal.ppat.1000171.s002 (2.29 MB TIF)
Figure S3 HIV-27312/V434M (+9 nM sCD4) and HIV-1MN
neutralization by sera from monkeys immunized 2 times with
gp140-F trimers formulated in the GSK Adjuvant System AS01B
or in Ribi adjuvant.
Found at: doi:10.1371/journal.ppat.1000171.s003 (1.12 MB TIF)
Figure S4 V3 peptide or gp120 binding reactivity in serum
samples from cynomolgus macaques, WT rabbits or huCD4
rabbits after immunization with gp140-F trimers.
Found at: doi:10.1371/journal.ppat.1000171.s004 (2.12 MB TIF)
Figure S5 Staining and gating strategy for flow cytometry
analysis of rabbit PBMCs.
Found at: doi:10.1371/journal.ppat.1000171.s005 (2.12 MB TIF)
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